Kang Stem Biotech has completed the subject evaluation of phase 3 clinical trials for Furestem-AD, the world's first stem cell treatment for atopy, and announced the completion of the trial.
The company had conducted the trial at 11 local medical institutions, including St. Mary's Hospital, Seoul National University Hospital, and Asan Medical Center, and in 197 chronic atopic dermatitis patients from April last year.
"Despite the trial being unusually big for a stem cell therapy, the company managed to complete administering the treatment in nine months," the company said." The clinical trials were completed within one year and seven months after the six-month observation period."
Kang Stem Biotech plans to disclose the final clinical results at the end of the year and apply for sales approval in the first quarter of next year.
"We will do our best to commercialize the product in Korea and enter phase 2 clinical trial in Europe until next year," CEO Lee Tae-hwa said.
<© Korea Biomedical Review, All rights reserved.>